Evidence map›Paper›PMID 19787069›Full record

ArticlePloS one2009

miR-200 enhances mouse breast cancer cell colonization to form distant metastases.

Derek M Dykxhoorn, Yichao Wu, Huangming Xie, Fengyan Yu, Ashish Lal, Fabio Petrocca, Denis Martinvalet, Erwei Song, Bing Lim, Judy Lieberman

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03457467 (Clinical Study of Apatinib Mesylate Combined With Stereotactic Body Radiation Therapy in the Treatment of Oligometastasis of Breast Cancer), which is not on this map. Cited by 192 papers.

0numbers the graph read from it
0cells of the map it votes in
192citing papers in PubMed
10.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03457467 phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Clinical Study of Apatinib Mesylate Combined With Stereotactic Body Radiation Therapy in the Treatment of Oligometastasis of Breast Cancer

TypeinterventionalSponsorYan LiRan2018 to 2020Enrolled30ConditionsBreast CancerArmsApatinib, SBRT
3 · Its place in the literature

Who cites it

192 citing papers in PubMed, 322 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. An engineered niche delineates metastatic potential of breast cancer.Bioengineering & translational medicine · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Review
  20. Article

132 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Derek M DykxhoornDepartment of Pediatrics, Immune Disease Institute, Harvard Medical School, Boston, Massachusetts, United States of America. ddykxhoorn@med.miami.edu
Yichao Wu
Huangming Xie
Fengyan Yu
Ashish Lal
Fabio Petrocca
Denis Martinvalet
Erwei Song
Bing Lim
Judy Lieberman
Harvard University · USGenome Institute of Singapore · SGSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe development of metastases involves the dissociation of cells from the primary tumor to penetrate the basement membrane, invade and then exit the vasculature to seed, and colonize distant tissues. The last step, establishment of macroscopic tumors at distant sites, is the least well understood. Four isogenic mouse breast cancer cell lines (67NR, 168FARN, 4TO7, and 4T1) that differ in their ability to metastasize when implanted into the mammary fat pad are used to model the steps of metastasis. Only 4T1 forms macroscopic lung and liver metastases. Because some miRNAs are dysregulated in cancer and affect cellular transformation, tumor formation, and metastasis, we examined whether changes in miRNA expression might explain the differences in metastasis of these cells. METHODOLOGY/PRINCIPAL

findingsmiRNA expression was analyzed by miRNA microarray and quantitative RT-PCR in isogenic mouse breast cancer cells with distinct metastatic capabilities. 4T1 cells that form macroscopic metastases had elevated expression of miR-200 family miRNAs compared to related cells that invade distant tissues, but are unable to colonize. Moreover, over-expressing miR-200 in 4TO7 cells enabled them to metastasize to lung and liver. These findings are surprising since the miR-200 family was previously shown to promote epithelial characteristics by inhibiting the transcriptional repressor Zeb2 and thereby enhancing E-cadherin expression. We confirmed these findings in these cells. The most metastatic 4T1 cells acquired epithelial properties (high expression of E-cadherin and cytokeratin-18) compared to the less metastatic cells. CONCLUSIONS/SIGNIFICANCE: Expression of miR-200, which promotes a mesenchymal to epithelial cell transition (MET) by inhibiting Zeb2 expression, unexpectedly enhances macroscopic metastases in mouse breast cancer cell lines. These results suggest that for some tumors, tumor colonization at metastatic sites might be enhanced by MET. Therefore the epithelial nature of a tumor does not predict metastatic outcome.

Indexed as

3' Untranslated RegionsAnimalsCadherinsCell Line, TumorCell Transformation, NeoplasticCloning, MolecularEpitheliumFemaleHomeodomain ProteinsKruppel-Like Transcription FactorsMammary Neoplasms, AnimalMiceMicroRNAsMicroscopy, FluorescenceNeoplasm MetastasisTreatment Outcome3' Untranslated RegionsCadherinsHomeodomain ProteinsKruppel-Like Transcription FactorsMicroRNAsMirn200 microRNA, mouseZEB1 protein, mouseZinc Finger E-box-Binding Homeobox 1

Identifiers

PMID19787069
PMCPMC2749331
OpenAlexW2059080364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.